Nixon Peabody
Bank of America
You are here:  Home  >  Banking & Finance  >  Current Article

Onyx buy sets dealmaking era for Amgen

By   /   Friday, August 30th, 2013  /   Comments Off on Onyx buy sets dealmaking era for Amgen

    Print       Email
Amgen’s $10.4 billion offer for South San Francisco-based Onyx Pharmaceuticals signals a new finance-oriented era of dealmaking under CEO and former investment banker Robert Bradway. Thousand Oaks-based Amgen, the world’s biggest biotechnology company, said Aug. 26 that it plans to offer $125 per share for Onyx, whose crown jewel is a recently approved blood cancer…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Mindbody’s Stollmeyer to be executive chair of the board

Read More →